This press release is an English-language translation of the original Japanese-language version. To the extent that there are discrepancies between this translation and the original version, the original version shall be definitive.

For Immediate Release

Daiichi Sankyo Co., Ltd.
Sanofi Pasteur KK

Announcement of application for approval in Japan of DPT-IPV vaccine for prevention of Diphtheria, Pertussis, Tetanus, and acute Poliomyelitis

TOKYO, Japan (February 20, 2013) – Daiichi Sankyo Co., Ltd.(Head office: Chuo-ku, Tokyo; President and Representative Director: Joji Nakayama; hereafter, Daiichi Sankyo) and Sanofi Pasteur KK (Head office: Shinjuku-ku, Tokyo; President: Thomas Triomphe) today announced that Kitasato Daiichi Sankyo Vaccine Co., Ltd. (Head office: Kitamoto city, Saitama; President: Masahiro Okabe), a member of the Daiichi Sankyo Group, has applied for approval of “tetralent combination vaccine (DPT-IPV)” in Japan for the prevention of Diphtheria, Pertussis (whooping cough), Tetanus, and acute Poliomyelitis (polio).

The DPT-IPV vaccine, which is supplied in pre-filled syringes, combines DPT vaccine from Kitasato Daiichi Sankyo and the enhanced inactivated Salk Poliomyelitis vaccine (eIPV), from Sanofi Pasteur.

The Daiichi Sankyo Group and Sanofi Pasteur contribute to the protection and improvement of people’s health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.

For further inquiries:

<table>
<thead>
<tr>
<th>Daiichi Sankyo Co., Ltd.</th>
<th>Corporate Communications Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>Media TEL: +81-3-6225-1126</td>
<td></td>
</tr>
<tr>
<td>Investors/Analysts TEL: +81-3-6225-1125</td>
<td></td>
</tr>
</tbody>
</table>
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About Sanofi Pasteur
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

About Sanofi Pasteur KK
Sanofi Pasteur KK offers Japan’s first Haemophilus Influenzae Type B (Hib) Vaccine and Standalone Inactivated Poliomyelitis Vaccine (IPV) for infants on top of Yellow Fever Vaccine since its launch in 1987. Sanofi Pasteur KK commits to contribute to Japan’s public health by introducing vaccines of global standard with safety and efficacy, by developing vaccines which have not been developed yet in the world in Japan as well. For more information, please visit: www.sanofipasteur.jp and www.vaccine-net.jp